BJDX stock icon

Bluejay Diagnostics


About: Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Employees: 10

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

42% more capital invested

Capital invested by funds: $243K [Q4 2023] → $345K (+$101K) [Q1 2024]

29% more funds holding

Funds holding: 7 [Q4 2023] → 9 (+2) [Q1 2024]

18.47% more ownership

Funds ownership: 16.09% [Q4 2023] → 34.57% (+18.47%) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for BJDX.

Financial journalist opinion